 |
|
|
| |
Efficacy and Safety of Glecaprevir/Pibrentasvir Treatment for 8 Weeks in Treatment-Naïve Patients With Chronic Hepatitis C Virus Infection Without Cirrhosis or With Compensated Cirrhosis: Analysis of Data Pooled From Phase 2 and 3 Studies
|
| |
| |
Reported by Jules Levin
EASL 54th Annual International Liver Congress, 10-14 April 2019, Vienna, Austria
Eli Zuckerman1, Julio A Guti errez2, Andrew Usti anowski3, Susanna Naggie4, Florin Caruntu5, Natarajan Ravendhran6, Samuel Sigal7, Lisa Barrett 8, Stanley Cohen9, Eric Crown10, Douglas Dylla10, Linda Fredrick10, Stanley Wang10, Ariel Porcalla10, Federico Mensa10, Savino Bruno11
1Carmel Medical Center, Haifa, Israel; 2St. Vincent Medical Center, Los Angeles, California, United States; 3North Manchester General Hospital, Manchester, United Kingdom; 4Duke University School of Medicine, Durham, North Carolina, United States; 5Nati onal Insti tute for Infecti ous Diseases "Prof Dr Matei Bals," Bucharest, Romania; 6Digesti ve Disease Associates, Catonsville, Maryland, United States; 7Montefi ore Medical Center, New York, New York, United States; 8Dalhousie University, Halifax, Nova Scoti a, Canada; 9UH Cleveland Medical Center, Cleveland, Ohio, United States; 10AbbVie Inc., North Chicago, Illinois, United States; 11Humanitas University and Humanitas Research Hospital, Milan, Italy
|
| |
|
|
|
|
|
